Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Removab in Platinum Refractory Epithelial Ovarian Cancer
NCT00189345Phase 2Completed
- Sponsor
- AGO Study Group
- Start
- May 2004
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of catumaxomab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by AGO Study Group. Started May 2004; status: completed.
02
Drugs
catumaxomab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00189345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189345.